Shanghai New Origin Pharmaceutical Group was established in 2001, located in Zhangjiang Medicine Valley, Pudong. It successively established branches in Taizhou, Wuhan, Wenzhou, and Guangzhou. In 2015, it became a wholly-owned subsidiary of Zhejiang Yatai Pharmaceutical (Shenzhen Stock Exchange code 002370). New Origin is a high-tech enterprise with the philosophy of realizing a healthy China and an innovative China, committed to serving the industrialization of innovative achievements, capitalizing on entrepreneurial ventures for transformation, and accelerating the internationalization of the health industry. New Origin's mission: accelerate the industrialization, marketization, and capitalization of innovative technologies. New Origin provides: one-stop professional services CHO for health and medical products. New Origin establishes: public service platform PCR for the health and medical industry chain. New Origin integrates: government, industry, medical, research, and capital resources for the development of the big health industry. New Origin's culture: entrepreneurial passion, innovative vitality, and excellence-creating mechanisms. 1. Main business of New Origin: pioneering the provision of full-process CRO services covering health and medical products. Service products include: pharmaceuticals (biological products, chemical drugs, natural medicines), medical devices (diagnostic reagents, medical equipment, medical consumables), and clinical diagnosis and treatment technologies; an industry-medicine-research collaborative innovation service model centered on the major disease prevention and control science and technology action plan. Commissioned by the Medical Science and Technology Development Research Center of the National Health and Family Planning Commission, New Origin undertakes the research, promotion, and service work of the major disease prevention and control science and technology action plan. 2. Advantages of New Origin: Large platform for technical services: New Origin has established a large platform for industry-medicine-research collaborative innovation services by integrating GLP, GCP, and GMP alliance resources in a GRDP manner. Preclinical research service platform for new drugs: China GLP Institution Alliance. Pilot-to-industrialization research service platform for new drugs: International Alliance for Pharmaceutical Industry-University-Research (GMP). Clinical research and promotion service platform for new drugs: Wenzhou Innovation and Collaboration Center, Translational Medicine Center of Guangdong Academy of Medical Sciences (GCP). Integrated innovation and entrepreneurship service platform: Relying on national industrial bases, New Origin builds innovation and entrepreneurship service platforms, achieving institutional and mechanism innovation integrating government, industry, medicine, research, and capital, and providing one-stop services for health and medical products and technologies. Wuhan Optics Valley New Drug Entrepreneurship Incubator (first batch of resident enterprises in 2009). China Pharmaceutical City Enterprise Incubation and Industrialization Base (first batch of resident enterprises in 2007). Wenzhou Yueqing Medical Island Town New Drug Industrialization Base. International medical service platform for health care: Shanghai Zhangjiang Medicine Valley Antibody and Personalized R&D Diagnosis and Treatment Center, Wenzhou Health Town. Special fund for major disease prevention and control and national special awards under the Achievement Transformation and Investment and Financing Promotion Alliance. Excellence-creating mechanisms integrate resources for the development of the big health industry from government, industry, medicine, research, and capital. 3. Company qualifications: Member of China Medicinal Biotechnology Association; National Shanghai Patent Technology Display and Trading Center; Post-doctoral scientific research workstation. Realize the value of biomedicine and strive to scale new heights in the bio-industry.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows